Dharmacon said this week that it has formed a collaboration with Merck’s Rosetta Inpharmatics unit to assess the different factors that impact the efficacy and specificity of siRNAs.
The partnership comes about four months after researchers from Rosetta published a paper in Nature Biotechnology (June 2003, 21: 6, 635-637) demonstrating that chemically synthesized siRNAs, provided by Dharmacon, caused off-target silencing effects in two separate experiments.